Mobile Health Support for HIV Prevention Pills and Doxycycline Among Young People
Tests a phone-based support package for HIV and STI prevention in young people.
Plain-language title generated from the registry record
Registry title: Combatting HIV Or Other STIs Early (CHOOSE)
Key facts
- Where
- Chicago, Memphis, New Orleans, San Francisco, Tampa, and Washington D.C., United StatesSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 13 and 24 years old?
Source: NCT07510048, who can take part
Where in United States
- University Illinois ChicagoChicago, United StatesTaking people
- St. Jude Children's Research HospitalMemphis, United StatesTaking people
- Tulane UniversityNew Orleans, United StatesTaking people
- San Francisco Department of Public HealthSan Francisco, United StatesTaking people
- University of South FloridaTampa, United StatesTaking people
- Children's National Medical CenterWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Westat
- Trial code
- NCT07510048
- Record updated
- 9 October 2026
- Original description
The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.Read full original descriptionShow less
Combatting HIV Or Other STIs Early (CHOOSE): An Integrated Strategy of Pre-Exposure Prophylaxis (PrEP) Mobile Health (mHealth) Support and Doxycycline Post-Exposure Prophylaxis (DoxyPEP)
The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.
Inclusion: Age 13-24 years, inclusive; Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime; Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package; Not currently on PrEP and interested in learning more about PrEP; Is not living with HIV; Weighs at least 35 kg; Willing to receive PrEP care from a provider at a participating ATN SC; Able to understand, read, and speak English; Able to participate at the study site; and; Willing and able to provide written informed consent; If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation; If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation.
Exclusion: Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study); Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team; In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months; Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results; Female; Plan to move within 18 months to an area inaccessible to a participating ATN SC; An employee of the participating SC; or.